First News

Parkinson’s disease treatment is used to treat the symptoms of Parkinson’s disease, generally, medication is the first line treatment for this disease. The  global  Parkinsons disease treatment market  is expected to reach USD 5.69 billion by 2022 from USD 4.24 billion in 2017, at a CAGR of 6.1% . Rising geriatric population and government funding for research on Parkinson’s disease are the driving factors for this market. Currently, a wide range of treatments is available for alleviating the symptoms of Parkinson’s disease. Medication is the first line therapy for treating the disease; however, they are not effective in all stages of the disease. In the severe stages, medications do not show pharmacological action in relieving disease symptoms. Neurologists perform thalamotomy, pallidotomy, or implant  deep brain stimulation  (DBS) devices in order to ease symptoms. Moreover, the focus on gene therapy research has increased. According to the Parkinson’s Disease...

Parkinson’s disease treatment is used to treat the symptoms of Parkinson’s disease, generally, medication is the first line treatment for this disease. Rising geriatric population and government funding for research on Parkinson’s disease are the driving factors for this market. The  global Parkinson’s disease treatment market  is expected to reach $5.69 billion by 2022 from $4.24 billion in 2017, at a  CAGR  of 6.1%. Segments The Parkinson’s disease treatment market is segmented on the basis of drug class, distribution channel, patient care setting, and region. On the basis of drug class, the market is segmented into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to account for the largest share of the market in 2017. The growth in this segment is primarily attributed to the potency of the drug. By distribution channel, the market is segmented into hospital...